The earnings call demonstrated strong performance in software and life sciences, robust cash flow management, and strategic share repurchases. However, significant challenges were noted in China due to policy changes, along with pressures from tariffs and declining academic/government revenues. Despite these challenges, the company maintained robust innovation and improved its ESG rating.

Company Guidance -

Q3 2025

During the Q2 2025 earnings call, Revvity provided guidance that reflected their ability to adapt to a dynamic market environment, with a focus on maintaining high performance levels despite challenges. The company reported 3% organic growth overall, led by a 4% organic growth in their Life Sciences business, notably with a 30% growth in the Signals software franchise. However, the Diagnostics segment grew by only 2% organically due to new challenges in China, specifically related to a change in hospital lab reimbursements under the diagnosis-related groups (DRG) policy, which affected diagnostic panel volumes. Despite these challenges, Revvity revised their full-year organic growth expectations to 2% to 4%, down from a prior range. The company also adjusted their EPS expectations to $4.85 to $4.95, a modest 1% decline. They emphasized robust cash flow generation, with $115 million of free cash flow in the quarter, a 90% year-to-date free cash flow conversion, and significant share repurchase activities totaling nearly $450 million in the first half of the year.

Record Software Orders

The Software business set a new record for orders in a single quarter, indicating strong future performance.

Strong Life Sciences Growth

Life Sciences business grew 4% organically, with Signals software franchise growing approximately 30%.

Robust Cash Flow

Generated $115 million of free cash flow, with a year-to-date conversion rate of 90%.

Aggressive Share Repurchases

Repurchased nearly $300 million worth of stock in Q2, totaling $450 million in the first half of the year.

Innovation in Diagnostics

Launched the IDS i20 platform, a breakthrough in specialty testing automation.

Improved ESG Rating

MSCI increased their overall ESG rating for Revvity to AAA, the highest level.

Revvity (RVTY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RVTY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	1.14 / -	1.28	―	―	―
Jun 29, 2025	2025 (Q2)	1.15 / 1.18	1.22	-3.28% (-0.04)	―	―
Apr 28, 2025	2025 (Q1)	0.95 / 1.01	0.98	3.06% (+0.03)
Jan 31, 2025	2024 (Q4)	1.37 / 1.42	1.25	13.60% (+0.17)
Nov 04, 2024	2024 (Q3)	1.13 / 1.28	1.18	8.47% (+0.10)
Jul 29, 2024	2024 (Q2)	1.12 / 1.22	1.21	0.83% (+0.01)
Apr 29, 2024	2024 (Q1)	0.94 / 0.98	1.01	-2.97% (-0.03)
Feb 01, 2024	2023 (Q4)	1.17 / 1.25	1.7	-26.47% (-0.45)
Oct 30, 2023	2023 (Q3)	1.19 / 1.18	1.51	-21.85% (-0.33)
Aug 01, 2023	2023 (Q2)	1.19 / 1.21	2.32	-47.84% (-1.11)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

RVTY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Apr 28, 2025	$94.22	$94.99	+0.82%
Jan 31, 2025	$126.65	$125.94	-0.56%
Nov 04, 2024	$120.79	$124.56	+3.12%
Jul 29, 2024	$114.84	$125.26	+9.07%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.